ArticleRheumatology advances in practice2026
Association of genetic variants with extravascular complications and cytokine production in Takayasu arteritis: a cross-sectional study.
Article in Rheumatology advances in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Genetic variants in the chromosome 21q22 (chr21q22) region are shared among patients with Takayasu arteritis (TAK), inflammatory bowel disease (IBD) and spondyloarthritis (SpA), contributing to specific macrophage inflammation. This study aims to clarify the impact of this region on the clinical and molecular phenotypes of TAK. Methods: In this cross-sectional study, 71 TAK patients from Keio University Hospital were included. Single-nucleotide polymorphisms (SNPs) in the chr21q22 region were identified through genomic DNA sequencing in 25 patients and serum proteome analysis was conducted in 17 patients. Interleukin-17C (IL-17C)-induced cytokine production was measured via whole blood cytometry by time of flight (CyTOF) in five patients with chr21q22 SNP accumulation and five without. Results: Among the 71 patients, 11% had IBD and 8.5% had SpA. Complications of IBD and SpA were strongly associated with chr21q22 SNP accumulation such as rs2242944, rs9808651 and rs2836882. Serum proteomic analysis revealed significantly elevated levels of IL-17C in TAK patients with chr21q22 SNP accumulation. IL-17C stimulation of whole blood from patients with chr21q22 SNP accumulation resulted in increased IL-6- and TNF-α-producing cells compared with those without SNP accumulation. Conclusion: SNPs in the chr21q22 region and elevated IL-17C levels may contribute to the pathophysiology of TAK-IBD-SpA comorbidity. These insights advance our understanding of the genetic and inflammatory mechanisms underlying extravascular complications in TAK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.